ADARx Pharmaceuticals (ADRX) files for Nasdaq IPO

ADARx Pharmaceuticals (ADRX) filed for a proposed Nasdaq IPO.

The company describes itself as: "We are a late-clinical stage biotechnology company focused on developing next-generation siRNA therapeutics designed to treat a broad spectrum of diseases. We are focused on advancing and expanding our pipeline of highly potent, selective and durable siRNA therapeutic candidates, including three clinical-stage programs and two advanced preclinical programs. Our goal is to control the expression of specific disease drivers with highly selective RNA targeted therapies, delivering life-changing treatments for patients with urgent unmet medical needs. Our team is united by a shared vision to build a leading next-generation siRNA therapeutics company."

J.P. Morgan, Morgan Stanley, TD Cowen, UBS Investment Bank and LifeSci Capital will serve as underwriters.

You May Also Be Interested In

• Capri stock surges on potential buyer interest report
• Marathon Petroleum (MPC) spreader of October 340 and 380 puts
• PayPal (PYPL) announces pact with Meta for Muse